Patients with preB ALL who expressed CYP3A5 showed less vincristine-induced peripheral neuropathy (VIPN), generated more M1, and had lower metabolic rates than those who did not express CYP3A5 [32]. This evidence concerns the gene CYP3A5 and acute lymphoblastic leukemia.